A follow up study [81] confirmed these results using genetic and pharmacologic inhibition of ERK activity, further exemplifying the notion that MEK/ERK signaling can antagonize the effect of JAK2 inhibitors, providing strong support for combining MEK or ERK inhibitors with JAK2 inhibitors in MPN (Fig. 1). The gene discussed is JAK2; the disease is myeloproliferative disorder.